key: cord-0029152-4bq9clhw authors: Burayk, Shady; Oh-hashi, Kentaro; Kandeel, Mahmoud title: Drug Discovery of New Anti-Inflammatory Compounds by Targeting Cyclooxygenases date: 2022-02-24 journal: Pharmaceuticals (Basel) DOI: 10.3390/ph15030282 sha: 6257fc24bd28d6656c864dc697621922bcbbbd5b doc_id: 29152 cord_uid: 4bq9clhw The goal of achieving anti-inflammatory efficacy with the fewest possible adverse effects through selective COX-2 inhibition is still being investigated in order to develop drugs with safe profiles. This work shows the efficacy and safety profile of two novel benzimidazole piperidine and phenoxy pyridine derivatives in reaching this goal, which would be considered a major achievement in inflammatory therapy. The compounds were evaluated by virtual screening campaign, in vitro cyclooxygenase 1 and 2 (COX-1 and COX-2) inhibition, in vivo carrageenan-induced rat paw edema assay, cytotoxicity against Raw264.7 cells, and histopathological examination of rat paw and stomach. Two new compounds, compound 1 ([(2-{[3-(4-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]carbonyl}phenyl)amino]acetic acid) and compound 2 (ethyl 1-(5-cyano-2-hydroxyphenyl)-4-oxo-5-phenoxy-1,4-dihydropyridine-3-carboxylate) showed high selectivity against COX-2, favourable drug-likeness and ADME descriptors, a lack of cytotoxicity, relived paw edema, and inflammation without noticeable side effects on the stomach. These two compounds are promising new NSAIDs. Inflammation is a chain of physiological responses involving a wide range of different molecules and cellular responses [1] . The mediators that emerge from two routes are particularly interesting from the perspective of drug research. Leukotrienes (LTs) are the first class of mediators that contribute to the inflammatory process, and they play a significant part in the inflammatory process overall. LTs are produced by the enzyme Arachidonate 5-lipoxygenase (5-LOX) [2, 3] . The second set is more diverse and comes in effect after the activity of COXs that convert arachidonic acid to prostaglandin. PGE2 and PGI2 increase blood flow in inflamed areas by their potent vasodilator action. Prostacyclin (PGI2) is responsible for platelet aggregation and vascular endothelium inhibition. The vasodilation effect of Prostacyclin E2 and Prostacyclin I2 contributes to the protection of the gastric mucosa by boosting mucus secretion and preventing an increase in acidity and pepsin content in the stomach. In kidneys, PGE and PGI play roles in increasing the flow of the blood and regulation of the glomerular filtration rate [4, 5] . Nonsteroidal anti-inflammatory drugs (NSAIDs) are a type of prescription that, when taken in sufficient amounts, can reduce pain, inflammation, blood clotting, and fever. NSAIDs may cause several side effects in patients, however, the most dangerous side effects include gastrointestinal ulcers, kidney problems, heart attacks, and bleeding [6] . Despite a few side effects, the drug's benefits outweigh the risks, making it a viable therapeutic option. NSAIDs are the gold standard in the treatment of inflammatory episodes due to their ability to block the arachidonic acid pathways [7] . NSAIDs act by selective or non-selective inhibition of both enzymes COX-1and COX-2 [8, 9] . In addition to lowering inflammation, non-selective medicines work by inhibiting the aggregation of platelets. Additionally, the medication raises the risk of stomach ulcers and bleeding. Gastrointestinal side effects are a prominent concern associated with the use of NSAIDs. These medications cause both direct and indirect irritation of the digestive tract. The acidic components of NSAIDs produce direct irritation of the stomach mucosa as well as inhibit COX-1, resulting in a decrease in prostaglandin levels. Prostaglandin secretion is suppressed throughout the gastrointestinal tract, which increases the formation of stomach acid and decreases the synthesis of mucus, bicarbonates, and the tropical effects of mucosa and epithelial cells [10] . To some extent, all NSAIDs can impair neutrophil activity, but indomethacin, piroxicam, ibuprofen, and all salicylates have the most dramatic effect [11] . There are fewer side effects with selective COX-2 inhibitors, and their gastrointestinal ulcerogenic properties are decreased as well [12] . The pursuit for a less toxic NSAID resulted in the release of two selective COX-2 inhibitors in 1999, celecoxib and rofecoxib [11] . No NSAID is a complete COX-1 or COX-2 inhibitor; rather, each enzyme is inhibited to varying degrees. Given the tremendous load posed by NSAIDs, COX-2 inhibitors appear to be a viable alternative for reducing the risk of major GI bleeding [11] . Therapeutic development will continue to rely extensively on computational tools to aid in the identification and validation of potential drug targets, which will help to accelerate the process [13] [14] [15] [16] . The field of bioinformatics is at the forefront of our efforts to better comprehend the workings of the cell. In order to produce hypotheses for testing, it is necessary to integrate enormous volumes of knowledge from numerous subdisciplines within molecular and cell biology into a cellular model that can be tested. We used such a compilation of methods to deliver new NSAIDs. The selection of such novel compounds was based on their general high selectivity on COX-2, ability to pass drug-likeness and ADME evaluations, strong anti-inflammatory activity, no stomach side effects, and safety when tested in human cell culture. The rationale behind this study was to discover new selective COX-2 inhibitors utilizing virtual screening of a library of chemical compounds that consisted of 1.2 million compounds from the Chembridge Inc core library. Following a two-step, virtual screening procedure that included standard precision docking (SP) followed by extreme precision docking (XP), the compounds with the highest docking scores were obtained from the database ( Figure 1 ). The compound docking scores and ligand efficiency are displayed in Table 1 . The compounds are accompanied by favourable hydrogen bonds and lipophilic scores as indicated by the negative values of Glide lipo and Hbond. By analyzing the ligand interactions of the docked compounds with COX-2 structure, several interaction forces maintained the complexes binding with COX-2, comprising salt bridges, stacking interactions, and hydrogen bonds ( Figure 2 ). Compound 1 formed a hydrogen bond and salt bridge with ARG120. Compounds 2, 3, and 6 formed salt bridges with ARG120. Compound 4 formed a stacking interaction with TYR355 and a hydrogen bond with SER530. Compound 5 formed a stacking interaction with TYR385 and salt bridge with SER530. Compound 6 formed a hydrogen bond with ARG120. Compound 7 formed a hydrogen bond with SER530. Collectively, salt bridges with ARG120, hydrogen bonds with TYR335 and SER530, or stacking interactions with TRY385 were the major interaction of the compounds with COX-2. ARG120 and TYR355 are two major residues at the construction site of COX-2. The projected selectivity of compounds against COX-2 can be concluded from the interaction with the side pocket of COX-2 composed of ARG513, ALA516, ILE517, PHE518, VAL523, and LEU531. Table 2 shows the predicted ADME parameters for the top seven compounds. With no infractions, all compounds passed Lipinski's rule of five. All compounds showed favourable mw, donor hydrogen bonds, acceptor hydrogen bonds, human oral absorption % (>30%), predicted IC50 value for blockage of HERG K+ channels (<5), absorption from skin (QPlogKp), intestinal absorption, crossing the blood-brain barrier, water accessible surface area, as well as its hydrophilic components. A few minor violations of the prediction parameters were also observed. Within the examined seven compounds, compounds 1-3 showed the highest selectivity index. Compounds 1-3 inhibited the enzymes with compound 1 IC 50 values of 11.68 ± 1.2 µM and 0.068 ± 0.008 for COX-1 and COX-2, respectively ( Table 3 ). The IC 50 for compound 2 was 12.22 ± 1.1 and 0.048 ± 0.002 µM for COX-1 and COX-2, respectively. The IC 50 for compound 3 was 11.11 ± 1.1 and 0.06 ± 0.003 µM for COX-1 and COX-2, respectively. The selectivity index for compound 1 was 124.5 and 68.7-fold higher than indomethacin and diclofenac, respectively. In contrast, it was 1.9-fold lower than celecoxib. Compound 2 has a selectivity index of 254.5, which is higher than compound 1 and makes it the most selective COX-2 inhibitor. Compound 3 was placed second on the selectivity index, with an SI value of 194.9. The carrageenan-induced paw edema model was used to evaluate the compounds' anti-inflammatory activity. Only carrageenan was given to the control animals. The treatment effect was tracked by observing the improvement of rat paw edema in response to drug administration. Carrageenan injections caused rat paws to grow from 0.3 cm to 0.8 cm in size. After 1 h of dosing, diclofenac and indomethacin dramatically reduced rat paw edema ( Figure 3 ). Compounds 1, 2, and 3 significantly reduced rat paw size, comparable to diclofenac and indomethacin. The size of the rat paw edema ( Figure 4 ) decreased significantly 30 min after the compounds and drugs were administered. The growth of the rat paw progressed in a substantially comparable manner 3-4 h after injection across all chemicals and medications examined. . The progress of rat paw edema (cm) for 5 h after compounds administration. The control group was treated with 0.2 mL of 1% carrageenan. Compounds 1, 2, and 3 were given orally at a dose rate of 10 mg/kg. The control nontreated group received NaCMC. The measurement was performed at 0, 30 min, 1, 2, 3, 4 and 5 h after administration of the drugs. Raw264.7 cells were used to test the effects of compounds 1, 2, and 3 on cell viability and proliferation. Raw264.7 cells were treated for 24 h in a 96-well plate with compounds (1 µM) in the presence or absence of LPS (1 ug/mL). WST1 reagent was added to each well after treatment and incubated for an additional 2 h. Following that, the OD450/620 ratio was determined. LPS treatment had a significant impact on cell morphology and proliferation. However, all compounds had no effect on WST1 values or cell morphology in Raw264.7 cells. Raw264.7 cells in a 96-well plate were treated with our compounds (1 uM) in the presence or absence of LPS (1 ug/mL) for 24 h. After treatment, the WST1 reagent was added into each well and incubated for an additional 2 h. After that, OD450/620 was measured. The control group sections of rat paw displayed a healthy paw tissue structure, exhibiting a typical intact epidermal layer of stratified squamous epithelium and dermal layer with ample capillaries and connective tissue cells ( Figure 5A,B) . Conversely, the carrageenan-injected paw tissue section examination showed substantial histopathological changes. There was increased dermis thickness attributable to edema with a marked inflammatory cell invasion of the deep dermis compared to the control group ( Figure 5C,D) . However, the compound 1-treated group exhibited marked improvement in the degree of edema and the inflammatory cell infiltration ( Figure 5E ,F). Interestingly, compound 2 exerted a marked anti-inflammatory effect and a pronounced decline in edema and inflammatory cell invasion ( Figure 5G ,H), which is almost similar to the impact of indomethacin; nevertheless, enhanced improvement in the degree of edema could be seen in the presence of compound 2. Compound 3 showed weaker action than compounds 1 and 2 manifested by a moderate increase in cell infiltration and edema ( Figure 5I ,J). (G) Photomicrograph of rat paw at 10× magnification of carrageenan-treated group followed by treatment with compound 2 showing a substantial decrease in both the inflammatory reaction (black star) and edema (Od). (H) Photomicrograph of rat paw at 40× magnification of carrageenan-treated group followed by treatment with compound 2 showing slight inflammatory reaction (black star) and edema (Od). (I) Photomicrograph of rat paw at 10× magnification of carrageenan-treated group followed by treatment with compound 3 showing a significant decrease in the degree of inflammatory reaction (black star) and a moderate decrease in edema (Od). (J) Photomicrograph of rat paw at 40× magnification of carrageenan-treated group followed by treatment with compound 3 showing moderate inflammatory reaction (black star) and edema (Od). (K) Photomicrograph of rat paw at 10× magnification of carrageenan-treated group followed by treatment with indomethacin showing a significant decrease in the degree of inflammatory reaction (black star) and a moderate decrease in edema (Od). (L) Photomicrograph of rat paw at 40× magnification of carrageenan-treated group followed by treatment with indomethacin showing slight inflammatory reaction (black star) and edema (Od). The degree of collagen deposition was investigated by Masson's stain as a qualitative indicator. Blue-green stained collagen was used for the purpose of assessing collagen deposition progression; the cytoplasm, red blood cells, and muscle were stained red. The density of the blue-green collagen is consistent with the relative amount of deposited total collagen fiber, which represents collagen synthesis, degradation, and remodeling. As shown by Masson's stain, there were more collagen fibers in the carrageenan group compared with the normal group ( Figure 6A ). Besides, among the treated groups, the collagen deposition was almost similar to the control nontreated group, except for compound 3. The quantity of collagen formation was the lowest in the compound 2-treated group and was better than indomethacin ( Figure 6B -E). The control group stomach sections displayed a healthy gastric tissue structure, exhibiting typical intact villi of gastric mucosa with no signs of hemorrhages or congestion; also there is no exfoliation in the mucosal epithelium or inflammatory cell infiltration ( Figure 7A,B) . Interestingly, compound 1, compound 2, compound 3 , and indomethacintreated groups did not show apparent histopathological changes ( Figure 7C-J) . The collagen deposition was almost similar to control nontreated animals in compounds 1 and 2 ( Figure 8A-F) . Conversely, compound 3 and indomethacin exerted a mild increase in collagen deposition ( Figure 8G -J). Despite the presence of several NSAIDs, the development of new NSAIDs is attractive, owing to the diverse inflammatory conditions and the need for optimized application in relation to disease and patient conditions. The recent development of NSAIDs comprises modified methyl sulphonyl [17] ; pyrimidine-5-carbonitrile hybrids [18] , pyrazole derivatives [19] , indanone containing spiroisoxazoline derivatives [20] , triazole, and oxadiazole compounds [21, 22] . Despite the growing repository of newly synthesized NSAIDs, the development of new compounds is strictly required due to the side effects of the currently approved NSAIDs. For instance, even in short-term applications, a high dose of ibuprofen resulted in jejunal perforations [23] ; naproxen affects bowel and jejunal integrity [24] . Within days of intake, diclofenac has been proven to raise the risk of heart attacks and strokes by 50% [25] . The intricate interplay between injured tissues and inflammatory cells, which results in the release of inflammatory mediators such as interleukins, necrotic factors, and enzymes such as cyclooxygenases and lipoxygenases, is a crucial aspect of inflammation [26] . The overexpression of COX-1 and COX-2 during inflammatory processes is crucial for the inflammatory signaling system [27] . Controlling inflammation can prevent excessive injury from an aggressive immune response or the development of chronic illness [28] . Drug molecules meet several membrane barriers on their kinetic voyage through the body, including the blood-brain barrier, gastrointestinal epithelial cells, and the membrane target cell. Predicting permeability behind barriers will aid in the prediction of pharmacokinetic parameters and the knowledge of chemical behavior within the body. QikProp estimates and predicts molecular characteristics and provides results for ADME (absorption, distribution, metabolism, and excretion) [29] . Lipinski's "Rule of Five" and the "Jorgensen Rule-of-Three" were used to determine drug-likeness. The "Jorgensen Rule-of-Three" is based on the qualities of over 90% of 1700 oral medications and meets the "rule of five", indicating that these molecules can be utilized as potent drugs/inhibitors [30] . The basic drug-likeness and ADME qualities of compounds 1-3 indicated generally acceptable parameters, particularly the absence of breaches of Lipinski's rule of five, good oral absorption, and lack of carcinogenic potential. This was further demonstrated experimentally by the absence of any harmful effect on Raw264.7 cells. Compounds 1-3 were compared to selective and nonselective COX inhibitors for cyclooxygenases inhibition. Compounds 1-3 inhibited COX-1 less well than indomethacin and diclofenac but were comparable to the selective medicines celecoxib and rofecoxib. When compared to the nonselective medication indomethacin, compounds 1-3 had at least a 100-fold lower impact on COX-1. Furthermore, all compounds inhibited COX-2 at lower concentrations than indomethacin and diclofenac, particularly compound 2, which was comparable to the selective drug celecoxib. The overall selectivity index was in the following order: rofecoxib < celecoxib < compound 2